keyword
MENU ▼
Read by QxMD icon Read
search

Sevelamer

keyword
https://www.readbyqxmd.com/read/28169559/challenges-in-diagnosing-medication-resins-in-surgical-pathology-specimens-a-crystal-clear-review-guide
#1
Raul S Gonzalez, Stephen M Lagana, Oliver Szeto, Christina A Arnold
CONTEXT: -Medication resins, including Kayexalate, sevelamer, and bile acid sequestrants, can be encountered in gastrointestinal tract specimens. Their classic histologic appearances have been well documented, but pathologist recognition of the resins is 75%, patient history is not always available, and atypical morphologic findings are sometimes present. OBJECTIVE: -To offer a succinct overview of resins in the gastrointestinal tract, including typical and atypical appearances, in order to serve as a quick reference guide...
February 7, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28153426/factors-affecting-gastrointestinal-absorption-of-levothyroxine-a-review
#2
REVIEW
Marko Skelin, Tomo Lucijanić, Daniela Amidžić Klarić, Arnes Rešić, Miro Bakula, Ana-Marija Liberati-Čizmek, Hossein Gharib, Dario Rahelić
PURPOSE: Levothyroxine (LT4) is a drug with a narrow therapeutic index, applied in small amounts (micrograms), which makes interactions in the absorption phase clinically significant. The main aim of this article was to review and present the latest information on factors that affect the gastrointestinal absorption of this drug. METHODS: Relevant data were collected by using the MEDLINE, PubMed, EMBASE, Web of Science, Science Direct, and Scopus databases with the key words levothyroxine and absorption...
January 30, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28068585/effects-of-phosphate-binders-on-the-gastrointestinal-absorption-of-arsenate-and-of-an-sglt2-inhibitor-drug-on-the-urinary-excretion-of-arsenite-in-mice
#3
Miklós Poór, Balázs Németi, Zoltán Gregus
Arsenate (As(V)) and arsenite (As(III)) are typical sources of acute and chronic arsenic poisoning. Therefore, reducing inner exposure to these arsenicals is a rational objective. Because As(V) mimics phosphate, phosphate binder drugs may decrease the intestinal As(V) absorption. Indeed, lanthanum and aluminium salts and sevelamer removed As(V) from solution in vitro, especially at acidic pH. In mice gavaged with As(V), lanthanum chloride, lanthanum carbonate and aluminium hydroxide given orally also lowered the urinary excretion and tissue levels of As(V) and its metabolites, indicating that they decreased the gastrointestinal As(V) absorption...
January 2017: Environmental Toxicology and Pharmacology
https://www.readbyqxmd.com/read/28064234/effect-of-calcitriol-on-fgf23-level-in-healthy-adults-and-its-dependence-on-phosphate-level
#4
Effrosyni Georgiadou, Helen Marketou, George Trovas, Ismene Dontas, Nikolaos Papaioannou, Konstantinos Makris, Antonios Galanos, Athanasios Papavassiliou
AIM: To evaluate the short-term effects of calcitriol and sevelamer hydrochloride on fibroblast growth factor-23 (FGF23) in humans and to determine whether the effect is direct or indirect through calcitriol-induced increased absorption of phosphorus from the intestine. PATIENTS AND METHODS: A total of 15 healthy individuals were tested at three time points and stages, for 24 h and at 1-week intervals. During each stage, blood samples were taken at three time points (0, 8 and 24 h); baseline stage: under no intervention; second stage, while receiving 0...
2, 2017: In Vivo
https://www.readbyqxmd.com/read/27989850/long-standing-diarrhea-associated-with-sevelamer-crystalopathy-in-colonoic-mucosa
#5
Rohan M Modi, Benjamin Swanson, Vijay Duggirala
No abstract text is available yet for this article.
October 27, 2016: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27971360/cost-minimisation-analysis-of-sucroferric-oxhydroxide-and-sevelamer-carbonate-in-patients-on-dialysis-with-secondary-hyperparathyroidism-in-six-european-countries
#6
J van Stiphout, P Vrouchou, P G Braunhofer, M Schwenkglenks, T D Szucs, P Blank
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971354/cost-per-responder-analysis-of-sucrofferric-oxhydroxide-versus-sevelamer-carbonate-in-patients-on-hemodialysis-in-europe
#7
M Connolly, N Kotsopoulos, P Vrouchou, E Dubois, S Walpen
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27965186/impact-of-sevelamer-hydrochloride-on-serum-magnesium-concentrations-in-hemodialysis-patients
#8
Ryota Ikee, Takayuki Toyoyama, Toko Endo, Masataka Tsunoda, Nobuo Hashimoto
Serum Mg levels are elevated in patients with renal insufficiency: harmful effects of hypomagnesemia have been reported in patients receiving hemodialysis (HD). In this cross-sectional study, which included 86 HD patients (male : female = 56:30, age 68 ± 12 years), we examined the clinical factors associated with serum Mg levels, with a focus on sevelamer, a phosphate binder widely used to control the hyperphosphatemia of HD patients. The mean serum Mg concentration among our patients was 2.48 ± 0.37 mg/dL (1...
April 1, 2016: Magnesium Research: Official Organ of the International Society for the Development of Research on Magnesium
https://www.readbyqxmd.com/read/27751671/economic-evaluation-of-sevelamer-versus-calcium-based-binders-in-treating-hyperphosphatemia-among-patients-with-end-stage-renal-disease-in-china
#9
Li Yang, Seng Chuen Tan, Can Chen, Xingzhi Wang, Xinya Li, Xiaoyan Yang
PURPOSE: To conduct a cost-effectiveness analysis study of sevelamer versus calcium-based binders (CBBs) in treating hyperphosphatemia among patients with end-stage renal disease (ESRD) in China. METHODS: A decision-analytic model of a lifetime horizon was used for base case analysis from the payers' perspective. The transition probabilities between different health states were derived from survival analysis. The overall survival of CBBs was derived from the Dialysis Clinical Outcomes Revisited study for up to 44 months and a Weibull regression model was used to extrapolate the overall survival to a lifetime horizon...
October 14, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27651467/the-efficacy-and-safety-of-sevelamer-and-lanthanum-versus-calcium-containing-and-iron-based-binders-in-treating-hyperphosphatemia-in-patients-with-chronic-kidney-disease-a-systematic-review-and-meta-analysis
#10
Steven Habbous, Sebastian Przech, Rey Acedillo, Sisira Sarma, Amit X Garg, Janet Martin
BACKGROUND: It remains unclear which phosphate binders should be preferred for hyperphosphatemia management in chronic kidney disease (CKD). METHODS: We performed a systematic review and meta-analysis of randomized trials comparing sevelamer or lanthanum with other phosphate binders in CKD. RESULTS: Fifty-one trials (8829 patients) were reviewed. Compared with calcium-based binders, all-cause mortality was nonsignificantly lower with sevelamer {risk ratio [RR] 0...
September 20, 2016: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/27615161/adherence-rates-to-ferric-citrate-as-compared-to-active-control-in-patients-with-end-stage-kidney-disease-on-dialysis
#11
Diana Jalal, Molly McFadden, Jamie P Dwyer, Kausik Umanath, Erwin Aguilar, Yoram Yagil, Barbara Greco, Mohammed Sika, Julia B Lewis, Tom Greene, Simin Goral
Introduction Oral phosphate binders are the main stay of treatment of hyperphosphatemia. Adherence rates to ferric citrate, a recently approved phosphate binder, are unknown. Methods We conducted a post-hoc analysis to evaluate whether adherence rates were different for ferric citrate vs. active control in 412 subjects with end stage kidney disease (ESKD) who were randomized to ferric citrate vs. active control (sevelamer carbonate and/or calcium acetate). Adherence was defined as percent of actual number of pills taken to total number of pills prescribed...
September 12, 2016: Hemodialysis International
https://www.readbyqxmd.com/read/27605663/sevelamer-improves-steatohepatitis-inhibits-liver-and-intestinal-farnesoid-x-receptor-fxr-and-reverses-innate-immune-dysregulation-in-a-mouse-model-of-non-alcoholic-fatty-liver-disease
#12
Brett M McGettigan, Rachel H McMahan, Yuhuan Luo, Xiaoxin X Wang, David J Orlicky, Cara Porsche, Moshe Levi, Hugo R Rosen
Bile acid sequestrants are synthetic polymers that bind bile acids in the gut and are used to treat dyslipidemia and hyperphosphatemia. Recently, these agents have been reported to lower blood glucose and increase insulin sensitivity by altering bile acid signaling pathways. In this study, we assessed the efficacy of sevelamer in treating mice with non-alcoholic fatty liver disease (NAFLD). We also analyzed how sevelamer alters inflammation and bile acid signaling in NAFLD livers. Mice were fed a low-fat or Western diet for 12 weeks followed by a diet-plus-sevelamer regimen for 2 or 12 weeks...
October 28, 2016: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/27577953/serum-endotoxin-activity-measured-with-endotoxin-activity-assay-is-associated-with-serum-interleukin-6-levels-in-patients-on-chronic-hemodialysis
#13
COMMENT
Maurizio Bossola, Enrico Di Stasio, Maurizio Sanguinetti, Brunella Posteraro, Manuela Antocicco, Gilda Pepe, Enrica Mello, Francesca Bugli, Carlo Vulpio
BACKGROUND: This study aims to evaluate, in patients on chronic hemodialysis (PHD), the levels of endotoxin through a chemiluminescent bioassay based on the oxidative burst reaction of activated neutrophils to complement coated LPS-IgM immune complexes and define the variables possibly correlated. METHODS: In 61 PHD, we measured serum endotoxin activity (EA) with the Endotoxin Activity Assay (EAA™) and we defined the possible association with demographic, clinical and laboratory variables...
2016: Blood Purification
https://www.readbyqxmd.com/read/27547398/sigmoid-colon-diverticula-perforation-associated-with-sevelamer-hydrochloride-administration-a-case-report
#14
Takahisa Yamaguchi, Shigekazu Ohyama, Hiroyuki Furukawa, Nariatsu Sato, Ichiro Ohnishi, Satomi Kasashima, Atsuhiro Kawashima, Masato Kayahara
INTRODUCTION: Sevelamer is an anion exchange resin used to treat hyperphosphatemia. A common adverse effect of sevelamer is constipation. According to a review of the available literature, colon perforation associated with this resin agent was less common. PRESENTATION OF CASE: A 66-year-old man complaining of lower abdominal pain was transferred to our hospital. The patient had been undergoing hemodialysis for chronic renal failure due to rapidly progressive glomerulonephritis, and had been receiving sevelamer hydrochloride 4...
September 2016: Annals of Medicine and Surgery
https://www.readbyqxmd.com/read/27545638/-iron-based-phosphate-binders-for-esrd-patients
#15
Mario Cozzolino, Michela Mangano, Lorenza Magagnoli, Luca Di Lullo, Andrea Galassi, Diego Brancaccio, Antonio Bellasi
Several factors influence the choice of phosphate binder for patients, including older age, male gender, post-menopause, diabetes, low bone turnover, vascular/valvular calcification and inflammation. Unlike calcium-based phosphate binders, non-calcium-based phosphate binders, such as sevelamer and lanthanum carbonate, have been able to reduce the progression of bone disease to adynamic bone among patients with CKD. New iron-based phosphate binders are now available. With multiple options available for the reduction of phosphate, the focus has been on agents that do not contain calcium...
July 2016: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/27496336/efficacy-and-safety-of-sucroferric-oxyhydroxide-compared-with-sevelamer-hydrochloride-in-japanese-haemodialysis-patients-with-hyperphosphataemia-a-randomised-open-label-multicentre-12-week-phase-iii-study
#16
Fumihiko Koiwa, Keitaro Yokoyama, Masafumi Fukagawa, Akira Terao, Tadao Akizawa
AIM: We aimed to investigate the non-inferiority of PA21 (sucroferric oxyhydroxide) to sevelamer hydrochloride (sevelamer) in terms of efficacy and safety in Japanese haemodialysis patients with hyperphosphataemia. METHODS: In this Phase III, open-label, multicentre study, 213 haemodialysis patients with hyperphosphataemia were randomised to PA21 or sevelamer treatment for 12 weeks. The primary outcome was adjusted serum phosphorus concentration at the end of treatment; the non-inferiority of PA21 was confirmed if the upper limit of the two-sided 95% confidence interval (CI) is ≤0...
August 6, 2016: Nephrology
https://www.readbyqxmd.com/read/27488565/sevelamer-crystals-in-the-bronchus-a-case-report
#17
Shroque Zaher, Ahsan Ali, Paul Babu
No abstract text is available yet for this article.
January 2017: Thorax
https://www.readbyqxmd.com/read/27461851/phosphate-binding-agents-in-adults-with-ckd-a-network-meta-analysis-of-randomized-trials
#18
Suetonia C Palmer, Sharon Gardner, Marcello Tonelli, Dimitris Mavridis, David W Johnson, Jonathan C Craig, Richard French, Marinella Ruospo, Giovanni F M Strippoli
BACKGROUND: Guidelines preferentially recommend noncalcium phosphate binders in adults with chronic kidney disease (CKD). We compare and rank phosphate-binder strategies for CKD. STUDY DESIGN: Network meta-analysis. SETTING & POPULATION: Adults with CKD. SELECTION CRITERIA FOR STUDIES: Randomized trials with allocation to phosphate binders. INTERVENTIONS: Sevelamer, lanthanum, iron, calcium, colestilan, bixalomer, nicotinic acid, and magnesium...
November 2016: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/27461215/can-intestinal-phosphate-binding-or-inhibition-of-hydroxyapatite-growth-in-the-vascular-wall-halt-the-progression-of-established-aortic-calcification-in-chronic-kidney-disease
#19
Ellen Neven, Britt Opdebeeck, Annelies De Maré, Rida Bashir-Dar, Geert Dams, Rita Marynissen, Geert J Behets, Anja Verhulst, Bruce L Riser, Patrick C D'Haese
Vascular calcification significantly contributes to mortality in chronic kidney disease (CKD) patients. Sevelamer and pyrophosphate (PPi) have proven to be effective in preventing vascular calcification, the former by controlling intestinal phosphate absorption, the latter by directly interfering with the hydroxyapatite crystal formation. Since most patients present with established vascular calcification, it is important to evaluate whether these compounds may also halt or reverse the progression of preexisting vascular calcification...
November 2016: Calcified Tissue International
https://www.readbyqxmd.com/read/27443567/cinacalcet-but-not-vitamin-d-use-modulates-the-survival-benefit-associated-with-sevelamer-in-the-independent-study
#20
RANDOMIZED CONTROLLED TRIAL
Antonio Bellasi, Mario Cozzolino, Domenico Russo, Donald Molony, Biagio Di Iorio
AIMS: Whether differences in outcomes of calcium-free vs. calcium-containing phosphate binder treatments can be amplified by concurrent treatment with a calcium-sensing receptor agonist or vitamin D remains to be elucidated. MATERIAL AND METHODS: A post-hoc analysis of the INDEPENDENT study, an open-label randomized controlled trial designed to evaluate the impact of sevelamer (SV) vs. calcium salts (CS) on survival in incident dialysis patients. RESULTS: We recruited 466 middle-aged men and women...
September 2016: Clinical Nephrology
keyword
keyword
24170
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"